Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Time spent managing disease, annual testing predict satisfaction in coeliac disease patients

07 Jan 2018
Savvy physicians should take advantage of these resources to deliver a message that presents their practices in the best light.

A recent survey has shown that coeliac disease (CD) care is satisfactory for a majority of patients who report higher approval when they feel physicians spend time caring for their CD needs and when they receive annual CD-antibody testing.

“On the basis of our study, these factors are more important than disease severity, seeing a CD specialist, and quality of life in determining patient satisfaction with CD care,” the authors said.

Of the 387 individuals (22 percent) who completed the survey, 229 met the inclusion criteria of biopsy-proven CD. With regard to their CD care, a total of 79 participants (34.5 percent) reported being “very satisfied,” 82 (35.8 percent) “satisfied,” 46 (20.1 percent) “neutral,” 14 (6.1 percent) “dissatisfied,” and eight (3.5 percent) “very dissatisfied.”

Multivariable analysis revealed that physicians spending ample time managing CD needs of patients (p=0.013) and having CD-antibody levels monitored every year positively predicted patient satisfaction. On the other hand, symptom severity (p=0.268), quality of life (p=0.13), and following with a CD specialist (p=0.139) did not correlate with patient satisfaction.

To assess how satisfied patients were with their CD care and to determine factors influencing satisfaction, the authors distributed an online questionnaire to adults receiving programmatic updates from a CD referral centre. The survey focused on aspects of CD care and used disease-specific validated instruments to measure quality of life and dietary adherence.

The authors also conducted univariable and multivariable analyses with the use of satisfaction as a binary outcome comparing grouped “satisfied” and “very satisfied” respondents to “neutral,” “dissatisfied,” and “very dissatisfied” respondents.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.